NCT06897605View on ClinicalTrials.gov

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Chronic Kidney Disease(CKD)Anemia, Kidney Disease, Chronic
Interventions
DRUG

Dapagliflozin (DAPA)

Dapagliflizin 10 mg tablets once daily for 12 weeks

DRUG

Erythropoiesis Stimulating Agent

Erythropoiesis stimulating agent (ESA) therapy

Trial Locations (1)

Unknown

RECRUITING

Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER